How to Choose a Healthcare Investment Banker: Registration, Deal Fit and a First-Meeting Test
Hire the banker whose legal status fits your deal, whose firm is built for your size and subsector, who writes the senior team into the engagement letter, whose fee you have modeled at three prices, and who names the issue that could break your deal before you raise it. Run five screens in this order:
- Confirm the advisor's legal status on FINRA BrokerCheck and in writing.
- Match the type of firm to your deal.
- Test who will staff the work.
- Negotiate the engagement letter.
- Test healthcare depth in the first meeting.
Most bad banker outcomes come from skipping one of the first three, not from picking a weak pitch book.
| Screen | Question it answers | Where it shows up |
|---|---|---|
| 1. Legal status | Can this advisor run this type of deal? | BrokerCheck and a written status statement |
| 2. Firm and deal fit | Is your deal a priority for this firm, and can it reach your buyers? | Firm-type and deal-type tables |
| 3. Staffing | Who does the work after the pitch team leaves? | Named team in the engagement letter |
| 4. Engagement letter | What will you pay, and how long are you bound? | Fee schedule, transaction value definition, tail |
| 5. Healthcare depth | Does the banker know your subsector's rules and buyers? | First-meeting questions and references |
Market data as of November 20, 2026. Each figure names its source, population and period, and links to the report. Figures are given as each source reported them, so confirm each one against the linked report before relying on it. Fee examples use illustrative terms and our own arithmetic. They are not market rates.
A Four-Week Selection Timeline
| Week | Work | Output |
|---|---|---|
| 1 | Build a long list of five to eight firms. Run every firm and named banker through BrokerCheck. Cut any firm whose status does not fit your deal type. | Short list of three or four |
| 2 | First meetings. Score the listen-first test and the specialty rule test. | Notes on each banker, in one format |
| 3 | Ask for written proposals with named teams. Model every fee at three prices. Call references, including one you found yourself. | Fee model and reference table |
| 4 | Send the review packet. Negotiate the engagement letter with your preferred banker. Hold a second firm in reserve until the letter is signed. | Signed letter with named team, fee definitions and tail list |
Four weeks is enough for most practice and platform sales. A banker who presses you to sign in the first meeting is showing you how they will run your process.
Screen 1: Registered Banker, Exempt M&A Broker or Finder
Three kinds of advisor put "healthcare investment banker" on a business card. Each works on a different legal footing, so check status before track record. For what the role covers, see what healthcare investment banking is.
| Advisor type | What it is | Built for | What to check |
|---|---|---|---|
| Registered broker-dealer | An SEC-registered FINRA member firm, with bankers registered through it | Sales, recapitalizations and capital raises, including minority rounds | The firm and every named banker on BrokerCheck: current status, current firm, disclosures |
| Exempt M&A broker | An advisor that relies on the federal exemption for brokers in sales of privately held companies | Control sales of private companies, within limits on size and structure | A written statement of the exemption it relies on and why your deal's size and structure fit it |
| Finder or consultant | A CPA, practice consultant or colleague who introduces buyers or investors | Introductions | What they do, how they are paid, by whom and whether pay depends on a closing. A flat fee does not settle the registration question by itself. Activities count too. |
Shortlist decision rule
| Advisor says | Ask for, in writing | Weak answer |
|---|---|---|
| "I'm registered" | The broker-dealer's name, matching BrokerCheck and the engagement letter | A different entity signs the engagement letter |
| "I'm exempt" | Why your specific deal fits, including size, structure and who the buyers are | "Everyone in practice sales works this way" |
| "I just make introductions" | What they do in the process and how they are paid | A success fee and an active role in negotiations |
A credible advisor answers each row in a sentence or two. A bar, suspension or unresolved customer complaint on BrokerCheck is a reason to ask hard questions or move on.
Sale versus raise: the line that sorts your shortlist
Federal and state rules on unregistered M&A brokers generally focus on control sales of private companies, carry their own conditions and vary by state, so ask your own securities attorney whether an advisor fits your deal. A raise from passive or non-controlling investors is placement work. That sorts the shortlist:
| Your deal | Start with |
|---|---|
| Control sale to a platform, sponsor or strategic | Registered broker-dealer or exempt M&A broker with a written basis |
| Minority growth round or physician-investor raise | Registered broker-dealer acting as placement agent |
| Hybrid, such as a majority recap with physician co-investors | Registered broker-dealer, or a written split of who runs each piece |
The review packet to assemble before you sign
Securities and healthcare counsel can review an advisor's status faster, and at lower cost, with a complete packet. Gather it during week 3:
- The draft engagement letter, including the signing entity, fee schedule, tail and exclusivity
- BrokerCheck printouts for the firm and every named banker
- The advisor's written statement of its registration status or exemption basis
- A one-page deal summary: control sale, recapitalization or minority raise, expected price range, and whether physicians or other individuals will invest or roll equity
- Everyone who may be paid in connection with the deal, including referral sources, with amounts and triggers
- Any existing letters of intent, indications of interest or prior engagement letters that may carry a tail
Deal mechanics to require from every advisor
Hold every advisor to these, registered or not, and ask your attorney how they bear on an exempt advisor's status.
- Money. Deposits, purchase price, holdbacks and indemnity escrows sit with a bank or escrow agent. An advisor that offers to route funds through its own account is a red flag.
- Signing. Only your authorized officers sign the LOI and purchase agreement.
- Financing. Ask whether the advisor or any affiliate offers acquisition debt, seller notes or bridge loans on your deal. If the banker introduces a lender to the buyer, ask what it is paid for that.
- Buyer groups. Ask whether the banker recruited or organized any member of the buying group, including physician syndicates.
- Dual roles. Ask whether the firm represents, or is paid by, any buyer or investor on the list.
Screen 2: Match the Firm to the Deal
Most mismatches come down to size and attention. A small mandate at a large bank gets junior staff. A complex carve-out run by a practice broker reaches too few buyers.
Firm-type fit
| Firm type | Deals it is built for | Buyer and investor reach | Risk for a healthcare seller |
|---|---|---|---|
| Large investment bank healthcare group | Health system mergers, public company deals, large platform exits | Strategics, large-cap PE, public markets | Your deal is small relative to the book and gets junior attention |
| Middle-market bank with a healthcare group | PE platform sales, large add-ons, recapitalizations, sponsor-to-sponsor deals | Middle-market PE, strategics, some family offices | Healthcare may be one group among many. Test subsector depth. |
| Healthcare specialist boutique | Physician, dental, ASC, behavioral, home health and healthtech platforms and add-ons | Specialty platforms, PE sponsors active in the subsector | Small bench. Confirm senior time and conflicts with buyer relationships. |
| Generalist lower middle-market M&A firm | Smaller control sales across industries | Broad but shallow in healthcare | Misses reimbursement, ownership and referral-law issues that drive price |
| Practice broker | Single-location practice sales, often to individual buyers | Local buyers, regional groups, some platforms | Registration status varies. Thin process for a multi-site group. |
| Registered placement agent | Minority growth rounds, physician-investor raises, family office co-investments | Family offices, growth investors, accredited individuals | Strong on raises, may lack sell-side execution |
Size sets the field. Kaufman Hall's Q3 2026 M&A report (October 13, 2026) put average seller size in announced US hospital and health system deals at nearly $586 million in annual revenue for the quarter. At the other end, individual buyers of small practices often finance with SBA 7(a) loans, which carry a program loan limit that can change, so confirm the current limit with the lender. A firm built for the first population is not the firm that sells a two-location dental practice, and the reverse holds too.
Deal-type fit
| Your deal | Advisor to shortlist | Interview question that sorts the field |
|---|---|---|
| Single-location practice sale to an individual buyer | Practice broker or small specialist firm | "How many of your buyers closed with SBA financing, and how do you pre-qualify them?" |
| Sale to a buyer already at the table | A banker for a limited scope, such as valuation support and negotiation, or no banker | "What does a full process add if the buyer is already set?" |
| Full sale to a PE platform or strategic | Registered broker-dealer or exempt M&A broker with platform relationships in your specialty | "Which platforms in my specialty have you closed with in the last two years?" |
| Add-on sale into an existing platform | Specialist boutique that runs competitive add-on processes | "How many platforms will you approach, and how will you get them to compete?" |
| Recapitalization with rollover equity | A banker who will diligence the buyer's holding company as hard as the buyer diligences you | "What will you get me on the platform's financials and debt before I roll equity?" |
| Family office taking control | Registered broker-dealer, or an exempt M&A broker whose written basis covers the structure | "How does the investor's role affect your basis to run this?" |
| Minority growth round from passive investors | Registered broker-dealer acting as placement agent | "Which registered firm is the placement agent?" |
| Physician-investor raise | Registered placement agent with healthcare securities experience | "How do you handle non-accredited physicians and referral-law issues?" |
| Hospital service line or practice divestiture | A banker with carve-out experience | "How do you separate shared contracts, staff and IT?" |
For the raise side, see capital raising for healthcare companies and raising capital from physician investors.
Where 2025 and 2026 deal flow went
Each row reports one dataset. Populations and periods differ, so do not compare rows with each other.
| Source, population and period | Data point | What it means for banker fit |
|---|---|---|
| CMS National Health Expenditure fact sheet: US physician and clinical services spending, 2024, with projections for 2025 to 2034 | Grew 8.1% in 2024, as reported by CMS. CMS projects 5.5% average annual growth from 2025 to 2034. | Buyers underwrite this growth. Your banker should show where your practice sits against it. |
| Bain press release, Global Healthcare PE Report 2026: global healthcare PE deal value, 2025 estimate | A record estimated $191 billion, above the 2021 peak | Capital is available. The banker's job is to reach the right part of it. |
| Same release: global provider and related services, 2025 estimate | An estimated $62 billion, up 57% on 2024 | Provider sellers compete with more live processes for buyer attention |
| Same release: healthcare IT within the provider segment, 2025 estimate | Doubled to an estimated $32 billion | Healthtech sellers need a banker who knows provider-side buyers |
| Same release: medtech, 2025 estimate | Value nearly doubled to an estimated $33 billion. Volume rose nearly 20% to an estimated 88 deals. | Device sellers need medtech buyer coverage, not a practice specialist |
| Bain, New Models of Value Creation for Physician Groups: global provider deals, 2025 actuals through November 30, 2025, annualized | North America accounts for more than 60% of global provider deal value. Deal volume is down from its 2021 peak, and physician groups remain a major part of many PE portfolios. | Check Bain's methodology for which add-ons it counts. Many small practice deals may fall outside large-deal datasets. |
| PESP, Private Equity Healthcare Deals: 2025 in Review: PE healthcare deals tracked from PitchBook and LevinPro HC, 2025 | 1,029 deals (151 buyouts, 664 add-ons, 214 growth investments) involving 708 investment firms. PESP says the count is likely an underestimate. | A buyer list built from memory misses most of the field |
| PESP data reported by Becker's ASC Review: PE deals involving outpatient care providers, 2025 | 148 deals, 119 of them add-ons. Our arithmetic: 119 / 148 = 80.4%. | Most tracked PE outpatient deals were add-ons into existing platforms. Ask which platforms the banker has closed with. |
| Same source: top outpatient subsectors by deal count, 2025 | Dermatology 24, eye care 22, oncology 9. Our arithmetic: 55 of 148, or 37.2%. | Specialty experience is concentrated, and you can check it |
| Kaufman Hall data reported by Becker's Hospital Review: announced US hospital and health system transactions | 22 in Q1, 18 in Q2 and 16 in Q3 2026, for 56 through September 30, 2026. All of 2025 had 46, the lowest annual count since Kaufman Hall began tracking in 2011. | Our arithmetic: the first nine months of 2026 exceed full-year 2025 by 10 deals. Hospital M&A is recovering from a low base. |
| Kaufman Hall Q3 2026 M&A report, October 13, 2026: Q3 2026 hospital and health system transactions | $8.2 billion in transacted revenue. Two megamergers, which Kaufman Hall defines as deals involving organizations with more than $1 billion in annual revenue. Divestitures were nearly one-third of deals. Not-for-profits were most of the acquirers. | Carve-out experience matters for hospital-owned practices and service lines |
| Same release: hospital financial data, year to date through August 2026 | Operating margin of 2.5% including allocations. Nearly 43% of hospitals operating at a loss. Non-labor expense per adjusted discharge up 6% on 2025, with supply expense up 5% and drug expense up 6%. | Health system buyers are price-sensitive. A banker selling to them should model the cost pressure they face. |
Screen 3: The Staffing Commitment Test
The partner who pitches is often not the person who runs your process. Senior bankers carry many live mandates, and the work falls to associates. Settle staffing before you sign, because your bargaining power drops once the letter is signed.
| Ask | Strong answer | Weak answer |
|---|---|---|
| Who is on the deal team, by name and role? | A named senior banker, a day-to-day lead and an analyst, all on BrokerCheck if the firm is registered | "We'll staff it once we're engaged" |
| How many live mandates does the senior banker carry today? | A specific number, and where your deal ranks | Avoids the question |
| Who attends buyer management meetings? | The senior banker, in person or on every call | "Whoever is available" |
| Who drafts the CIM and financial model? | The named day-to-day lead, with senior review | Outsourced or templated |
| Who negotiates LOI and purchase agreement points? | The senior banker, through signing | Handed off once the LOI is signed |
| What happens if the senior banker leaves? | A key-person clause lets you terminate, with a shorter tail | No answer |
Write the named team into the engagement letter. A key-person clause costs a firm nothing if it plans to staff the deal as promised.
Screen 4: The Engagement Letter
The engagement letter sets what you pay and how long you are bound. Negotiate it as hard as the purchase agreement.
| Term | What to negotiate | Seller-friendly version |
|---|---|---|
| Signing entity | Which legal entity is engaged | Matches the firm on BrokerCheck, or the exempt broker in your review packet |
| Named team | Who works the deal | Senior banker and day-to-day lead named, with a key-person clause |
| Retainer | Amount, timing and crediting | Staged against deliverables such as the CIM and buyer list, fully credited against the success fee |
| Success fee schedule | Flat, tiered or incentive tiers | Higher rates start only above a price you would be pleased with |
| Minimum fee | The floor payable at closing | Sized to the realistic price range, not the best case |
| Definition of transaction value | What counts toward the fee | Fees on earnouts and deferred payments due only when you receive them. Rollover equity and assumed debt addressed in writing. |
| Tail period | Length and scope after termination | Limited to parties the banker contacted and listed in writing |
| Exclusivity | Term and scope | A fixed term, limited to the mandate, with carve-outs for parties already talking to you |
| Termination | Who can end it and what survives | Either side on written notice. Termination for cause shortens or ends the tail. |
| Expenses | Reimbursable costs | Capped, with pre-approval above a set amount |
| Other fees on the deal | Fees from buyers, lenders or referral parties | All disclosed in writing |
Worked example 1: how the definition of transaction value moves the fee
Our arithmetic on illustrative terms, not market rates. Assumptions: the fee base is purchase price, the retainer is credited against the success fee, and expenses are excluded. A dermatology group signs a letter with a $25,000 monthly retainer and a success fee of 4% on the first $20 million of transaction value plus 2% above $20 million. The deal closes after 4 months at a $45 million purchase price: $38 million in cash at close plus a $7 million earnout.
| Step | Calculation | Result |
|---|---|---|
| Retainer paid | $25,000 x 4 months | $100,000 |
| Fee on first $20 million | 4% x $20 million | $800,000 |
| Fee on cash above $20 million | 2% x $18 million | $360,000 |
| Fee on cash at close | $800,000 + $360,000 | $1,160,000 |
| Due at close after retainer credit | $1,160,000 minus $100,000 | $1,060,000 |
| Fee on earnout, paid only if earned | 2% x $7 million | $140,000 |
| Total if the full earnout is paid | $100,000 + $1,060,000 + $140,000 | $1,300,000, or 2.89% of $45 million |
| Total if the earnout pays nothing | $100,000 + $1,060,000 | $1,160,000, or 3.05% of the $38 million collected |
If the letter computes the fee on the full $45 million at close, you pay the $140,000 on the earnout before you know whether you will receive it. If the earnout pays nothing, you have paid 2% on $7 million you never collected. One sentence in the definition of transaction value fixes this.
Worked example 2: comparing two fee proposals
Our arithmetic on illustrative terms, not market rates. Assumptions: a 6-month process, fees on purchase price, expenses excluded, the minimum applies to the total success fee and B's retainer counts toward it. Two bankers bid on the same multi-site physician group.
- Proposal A: $15,000 monthly retainer, not credited. Flat 3% success fee.
- Proposal B: $20,000 monthly retainer, fully credited. 2% on the first $25 million, 6% above $25 million. Minimum success fee of $600,000.
| Outcome | Proposal A total | Proposal B total |
|---|---|---|
| No deal closes | $90,000 retainer | $120,000 retainer |
| Sale at $24 million | 3% x $24 million = $720,000, plus $90,000 = $810,000, or 3.38% | 2% x $24 million = $480,000, below the minimum, so $600,000 including the credited retainer, or 2.50% |
| Sale at $30 million | 3% x $30 million = $900,000, plus $90,000 = $990,000, or 3.30% | $500,000 on the first $25 million plus 6% x $5 million = $300,000, so $800,000, or 2.67% |
| Sale at $40 million | 3% x $40 million = $1,200,000, plus $90,000 = $1,290,000, or 3.23% | $500,000 plus 6% x $15 million = $900,000, so $1,400,000, or 3.50% |
| Cost of each extra $1 million above $25 million | $30,000 | $60,000 |
Our arithmetic on where the lines cross:
- Low crossover, about $17 million. B's $600,000 minimum binds below about $26.7 million. A equals $600,000 when 3% of price plus $90,000 = $600,000, at $17 million. Below that, A is cheaper.
- High crossover, about $36.3 million. 3% of price plus $90,000 equals $500,000 plus 6% of the price above $25 million at $36.33 million, where each totals about $1.18 million. Above that, A is cheaper.
- Between $17 million and $36.3 million, B is cheaper. B also costs $30,000 more if no deal closes.
B suits a seller who expects a price in the high $20 millions to low $30 millions and wants the banker paid hard to push past $25 million. A suits a seller who expects $40 million or more, or a small deal. Run every proposal through your low, expected and high price before you compare headline rates.
Worked example 3: rollover equity and the fee base
Our arithmetic on illustrative facts. Assumptions: no debt, so equity value equals purchase price, and a flat 3% success fee. An ASC sells at a $40 million equity value. The owners take 70% in cash ($28 million) and roll 30% ($12 million) into the buyer's holding company.
| Fee base | Calculation | Fee at close | Fee as a share of cash received |
|---|---|---|---|
| Total value, including rollover | 3% x $40 million | $1,200,000 | $1,200,000 / $28 million = 4.29% |
| Cash only | 3% x $28 million | $840,000 | 3.00% |
| Difference | 3% x $12 million rollover | $360,000 | Paid in cash on equity you have not sold |
Bankers argue that rollover is part of the value they created, and some sellers accept a fee on it. Make that choice on purpose. If you pay on rollover, ask to defer that portion until the rollover equity is sold.
Tail period: the clause that outlives the banker
Suppose you end the engagement on March 1 under a 12-month tail and sign with a buyer in June. If the tail covers only parties on the banker's written contact list, a buyer the banker never approached generates no fee. If it covers "any transaction," the banker earns a full fee on a buyer it never met. Make the contact list a deliverable due within 30 days of termination.
Referral Payments to Your CPA or Consultant
Healthcare deals often start with an introduction from a practice consultant, a CPA or a colleague. When a banker offers to "take care of" the person who referred you, treat it as a diligence item. FINRA rules limit what member firms can pay unregistered people, and a closing-contingent fee can raise registration questions for the person paid.
- Ask whether any referral or finder payment is tied to your deal.
- Ask who pays it, how much and on what trigger.
- Ask whether the firm has documented its analysis of the payment.
- Get every fee arrangement connected to your deal disclosed in writing, including payments to your own advisors.
An adviser who takes an undisclosed referral payment is working for the banker as well as for you. A firm that cannot explain how it handles a small referral payment is showing you how it handles compliance in general.
Screen 5: Healthcare Depth
Deal count tells you an advisor is busy. It does not tell you whether they understand your corner of healthcare.
The specialty rule test (interview heuristic)
A dental service organization, an anesthesia group and a behavioral health platform each carry their own ownership rules, payer exposure and buyer universe. Ask the banker to name the issue that could break your deal before you raise it. A banker with current healthcare experience brings these up unprompted:
- Ownership structure. How corporate practice of medicine or dentistry rules in your state shape who can own the practice and how a management services structure fits.
- Restrictive covenants. Whether your state limits physician noncompetes, and how a buyer protects the goodwill it pays for if it does.
- State transaction review. Whether your state requires notice or review of healthcare transactions, and what that adds to the timeline.
- Referral relationships. Whether rollover equity or post-close employment raises questions under federal self-referral rules or federal referral payment rules, a question to take to your healthcare attorney.
- Buyer constraints. Which buyers operate under regulatory orders or pending government actions that affect timing or structure, and how the banker finds out.
- Federal premerger notice. Whether your price and the buyer's size could call for an FTC premerger filing, and how much preparation time to build in.
See the healthcare compliance due diligence guide.
Signs of a generalist (interview heuristic)
League tables treat "healthcare" as one sector, which hides how thinly a firm may be spread across hospitals, devices, pharma services and physician practices.
- If healthcare is one of a dozen industry tiles on the website, the label proves nothing.
- Ask for the firm's last five healthcare deals, how many were in your subsector and which person on the proposed team worked on each.
- Ask how payer mix, coding risk and provider retention affected price on a recent deal.
- For a raise, check the placement agent's claimed rounds on SEC EDGAR full-text search. Many private issuers file Form D notices, which can list recipients of sales compensation. A filing may not name every party involved or show who did what, so treat a firm's absence as a question to ask, not as proof.
- Read what the banker publishes. Public writing that teaches your subsector's rules is depth you can check.
The First Meeting: Listen-First Test (Interview Heuristic)
A banker who arrives with a valuation range and a buyer list before learning anything about your business is pitching before understanding it. Note which of these the banker asks about before opening a pitch book:
- Your goals: full exit, partial liquidity, growth capital or succession
- Your partners and how aligned they are on timing and price
- Payer mix and contract concentration
- Your timeline and anything forcing it
- Post-close work plans and any rollover equity
- Earlier conversations with buyers or investors
There is no passing score. Compare across bankers. The one who asked the most of these before pitching understood your deal best by the end of the meeting.
Selectivity (interview heuristic)
BrokerCheck and deal announcements show what a banker closed, not what it turned down. The turned-down mandates tell you more. A banker who brings buyers only sellable companies keeps getting their calls answered. Ask how many engagements the firm declined in the past year and what would make it decline yours.
The buyer list and outreach plan (interview heuristic)
Ask the banker to split the list into two groups. The first is buyers with healthcare experience: platforms in your specialty, health systems and family offices built from sector exits. The second is a short, deliberate set of non-specialists with a reason to want you. In the PESP outpatient data above, 80.4% of tracked 2025 PE outpatient deals were add-ons, which suggests platforms deserve heavy weight on the list for a PE-backed sale. For how investor types differ, see finding healthcare investors.
Then ask whose interests shaped the list. Ask whether any buyer or investor on it is a current or past client of the firm, and whether the firm earns a fee from that side too. Run your own reverse due diligence on the buyers the banker favors.
- How many parties will receive the teaser, and how was the list built?
- What is the first-contact method for each buyer type?
- Who on the team takes the first meeting with each buyer?
- How will passes be reported, and will buyers be asked for a clear yes or no with a reason?
A teaser sent in a mass email gets filtered out by the buyers you most want. A process full of soft maybes leaves you waiting on buyers who have already passed.
To get your financials ready before marketing begins, see preparing a healthcare company for sale.
References: The Off-List Call and Six Questions (Interview Heuristic)
References the banker picks will describe good outcomes. Find at least one former client on your own, ideally one whose deal did not close, and ask how the banker behaved when it fell apart. If you take rollover equity, you may be tied for years to the buyer the banker brought you.
Ask every reference the same questions and record the answers in one table:
| Question for the former client | What it measures | Answer that should worry you |
|---|---|---|
| How many buyers or investors did the banker contact, and how many met with you? | Outreach targeting | A large send with few meetings |
| Did the senior banker stay on the deal through closing? | Staffing commitment | The senior banker disappeared after the LOI |
| Did price or terms move after the LOI, and why? | Diligence preparation | A late reprice over an issue the banker never flagged |
| Who held escrow and who signed the documents? | Deal discipline | The banker or an affiliate held funds or signed |
| Were any referral or finder payments made, and were they disclosed to you? | Fee transparency | Payments you learned about only at closing |
| Did the tail or fee definitions cause a dispute? | Engagement letter terms | A fee claimed on a buyer the banker never contacted |
High-risk area: Who can be paid to sell your company or bring in investors
The rules on who may be paid to run a sale, place an investment or make an introduction are strict, change often and turn on your state, your deal structure and the facts. Engage a securities attorney, working alongside a healthcare attorney for the healthcare pieces, and bring these questions.
Questions to ask your attorney
1. Does this advisor's registration status, or the exemption it relies on, fit my specific deal?
- Why ask: Advisors describe their status in different ways, and the fit can depend on deal size, structure and who the buyers or investors are.
- What can go wrong: Questions about the engagement or the fee surface late in the process, when changing advisors is hardest.
2. If my deal mixes a control sale with a minority or physician co-investment piece, can one advisor handle every part?
- Why ask: Hybrid deals such as a majority recap with physician co-investors can sit across more than one category.
- What can go wrong: One piece falls outside what the advisor can do, forcing a restructuring or a second advisor mid-process.
3. Can anyone who referred me, such as my CPA, consultant or a colleague, be paid in connection with this deal, and on what terms?
- Why ask: Referral and finder payments, especially closing-contingent ones, can raise questions for both the payer and the person paid.
- What can go wrong: An undisclosed or poorly structured payment creates a conflict for your own adviser and can complicate the deal.
4. If physicians invest or roll equity, how should the offering and the referral relationships be handled?
- Why ask: Physician investors raise securities offering questions and healthcare referral questions at the same time.
- What can go wrong: Ownership or returns that track referrals draw scrutiny, and offering mistakes are hard to fix after money has been taken.
5. Do the engagement letter's signing entity, fee structure and tail raise any concerns given the advisor's status?
- Why ask: The signing entity and the success fee trigger should match what the advisor has told you about its status.
- What can go wrong: A mismatch between the signing entity and the registered firm leads to disputes over what is owed.
6. Could state healthcare transaction review or federal premerger notice apply, and how should they shape the timeline the banker quotes to buyers?
- Why ask: Filings and waiting periods set the signing-to-closing schedule and what you can promise buyers.
- What can go wrong: A timeline built without them slips after signing and weakens your position on price and terms.
- How states have handled it: States kept adding and amending healthcare transaction notice and review laws through 2026, as tracked in Bass, Berry & Sims' summary of 2026 state legislative updates.
7. If the banker also represents or is paid by a buyer or investor, what disclosure and consent should I ask for?
- Why ask: Dual roles can be disclosed and consented to, but consent does not change whose interests the banker serves on price.
- What can go wrong: You learn of a conflict only at closing, after the banker has shaped the buyer list and negotiations.
Other topics to raise with your attorney
- Tax treatment of cash, rollover equity and earnouts, and how it bears on the fee base definition
- Corporate practice of medicine or dentistry and the ownership structure a buyer proposes
- Noncompetes and other restrictive covenants for selling physicians
- Escrow, holdback and signing authority arrangements in the purchase agreement
- Prior engagement letters or tails that may still apply
Your 2026 Banker Interview Scorecard
Bring this to every interview and get written answers where you can.
| Item | What a good answer looks like | Where to check |
|---|---|---|
| Registration | Names the broker-dealer, matching BrokerCheck, or gives a written exemption basis tied to your deal | BrokerCheck, review packet |
| Disciplinary history | Clean records for every named team member | BrokerCheck |
| Firm-type fit | Your deal sits in the firm's core size range and subsectors | Firm-type table |
| Deal-type fit | Control sale: registered firm or exempt broker with a written basis. Minority or physician raise: registered placement agent. | Deal-type table |
| Staffing | Named senior banker and day-to-day lead in the letter, with a key-person clause | Staffing test |
| Funds and signing | A bank or escrow agent holds money. Only your officers sign. | Deal mechanics |
| Financing and buyer groups | No affiliate financing, disclosed pay for lender introductions, no buyer group assembled by the banker | Deal mechanics |
| Dual roles | Discloses any buyer or investor the firm also represents or is paid by | Deal mechanics |
| Referral fees | Every payment tied to your deal disclosed in writing | Review packet |
| Fee proposal | Modeled at your low, expected and high price, including the no-deal case | Worked example 2 |
| Transaction value definition | Earnout fees due when earned, rollover treatment settled in writing | Worked examples 1 and 3 |
| Tail and exclusivity | Tail limited to a written contact list, fixed exclusivity, either side can terminate | Engagement letter table |
| Specialty rules | Names your subsector's ownership, noncompete, referral or state review issue before you do | Specialty rule test |
| Premerger and state review | Raises timing and filing preparation unprompted | Specialty rule test |
| Placement track record | Claimed raises are consistent with Form D filings, with any gaps explained | SEC EDGAR |
| Selectivity | Describes mandates it declined and why | Interview heuristic |
| Outreach plan | Named list, targeted first contact, clear reporting of passes | Interview heuristic |
| Listen-first | Asks about goals, partners, payers and timeline before pitching | Interview heuristic |
| References | Gives you a client whose deal failed and holds up on the six questions | Interview heuristic |
For how sell-side and buy-side mandates differ, see sell-side vs buy-side. For what happens after you hire, see the healthcare M&A process, step by step.
Questions practice owners and investors ask
Does the advisor selling my medical practice have to be a registered broker-dealer?
Not always. Some advisors run sales of privately held companies under a federal exemption from broker-dealer registration. Whether an exemption fits your deal, and how your state treats it, is a question for your own securities attorney. Look up the firm and every named banker on FINRA BrokerCheck. If the advisor is not registered, get its exemption basis in writing, tied to your deal's size and structure, and have it reviewed before you sign. For a raise from passive investors, hire a registered broker-dealer.
Can the same advisor handle both a sale and a minority raise?
A registered broker-dealer can run both. An exempt M&A broker is built for sales of private companies. A raise from passive or non-controlling investors is placement work, and the clean answer is a registered firm. For a hybrid deal, such as a majority recap with physician co-investors, hire a registered firm or get in writing who runs each piece.
Can one banker represent both me and the buyer?
It happens. A credible advisor discloses in writing which parties it represents and gets written consent from each side before acting. Consent documents the conflict. It does not change whose interests the banker serves when price is negotiated. If someone proposes a dual role, ask what each side pays and who negotiates price for you.
Should my banker raise antitrust and state review early?
Yes. Federal premerger notice and state healthcare transaction review can add filings and waiting periods, and they shape the signing-to-closing timeline the banker quotes to buyers. A banker who quotes a closing date without asking about either has not done the work. Build both into the timetable before the teaser goes out.
Can a banker pay the CPA or consultant who referred me?
Not freely. FINRA rules limit what member firms can pay people who are not registered, and a fee that depends on your deal closing can raise registration questions for the person who receives it. Ask the banker in writing whether anyone who advised you is paid anything from the deal. Your CPA should be working for you, not the banker.
What does a healthcare investment banker cost?
Six terms set the cost: the retainer and whether it is credited, the success fee schedule, any minimum fee, the definition of transaction value, the tail and expenses. On this guide's illustrative terms, a $45 million sale on a 4% and 2% tiered fee costs $1.3 million, or 2.89% of price, if the full earnout pays. A tiered schedule can be cheaper at one price and more expensive at another, so model every proposal at your low, expected and high price.
Sources
- FINRA BrokerCheck, FINRA, accessed November 2026
- FINRA rule on payments to unregistered persons, FINRA
- EDGAR Full-Text Search, U.S. Securities and Exchange Commission
- National Health Expenditure Fact Sheet, Centers for Medicare & Medicaid Services, 2024 data and 2025 to 2034 projections
- 7(a) Loans, U.S. Small Business Administration
- Premerger Notification Program, Federal Trade Commission
- Fraud and Abuse Laws, HHS Office of Inspector General
- Physician Self-Referral, Centers for Medicare & Medicaid Services
- Global Healthcare Private Equity Report 2026, press release, Bain & Company, 2026
- New Models of Value Creation for Physician Groups, Bain & Company, Global Healthcare Private Equity Report 2026
- Private Equity Healthcare Deals: 2025 in Review, Private Equity Stakeholder Project
- The outpatient specialties that dominated 2025 deal activity, Becker's ASC Review, reporting PESP data
- Hospital M&A on pace for busiest year since pandemic, Becker's Hospital Review, reporting Kaufman Hall Q3 2026 data
- Q3 2026 M&A Quarterly Activity Report press release, Kaufman Hall, October 13, 2026
- Session's Out: Summary of State Health Care Transaction Legislative Updates Since January 1, 2026, Bass, Berry & Sims, 2026